Published in Lancet on April 07, 1984
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet (2009) 7.96
Prognosis of treated hypertension. Changes in life expectancy and causes of death between 1952 and 1967. Q J Med (1970) 3.71
Incidence of a positive direct coombs test in patients on alpha-methyldopa. Lancet (1966) 2.44
Drugs and the liver. Clin Pharmacol Ther (1998) 2.23
Positive direct Coombs tests and antinuclear factor in patients treated with methyldopa. Lancet (1967) 2.22
Drug interactions with warfarin: studies with dichloralphenazone, chloral hydrate and phenazone (antipyrine). Clin Sci (1971) 2.11
Hypertension and hyperuricaemia. Lancet (1966) 1.86
Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest (1974) 1.85
Dose-dependent enzyme induction. Clin Pharmacol Ther (1973) 1.84
Clinical implications of enzyme induction. Ann N Y Acad Sci (1971) 1.76
Changes in plasma -glutamyl transpeptidase activity associated with alterations in drug metabolism in man. Br Med J (1973) 1.76
Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet (1987) 1.70
Changes in liver blood flow during enzyme induction. Biochem Pharmacol (1971) 1.65
Kinetics of warfarin absorption in man. Clin Pharmacol Ther (1974) 1.63
Interindividual differences in rates of drug oxidation in man. Drug Metab Dispos (1974) 1.63
Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet (1966) 1.61
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther (1974) 1.61
Clinical pharmacology and therapeutics in undergraduate medical education in the UK: current status. Br J Clin Pharmacol (1994) 1.53
Treating mild hypertension. Br Med J (Clin Res Ed) (1985) 1.49
The disposition of amodiaquine in man after oral administration. Br J Clin Pharmacol (1987) 1.49
The effect of phenobarbitone-induction on vitamin D metabolism. Clin Sci (1972) 1.46
Postgraduate education in therapeutics: experience in Merseyside. Br Med J (1978) 1.44
Hypertension in the young. Q J Med (1967) 1.42
Regulatory challenges, reimbursement, and risk-benefit assessment. Clin Pharmacol Ther (2010) 1.32
Immediate decrease by hydrocortisone of the plasma half-life of antipyrine. Br J Pharmacol (1973) 1.28
Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS (1994) 1.25
Methyldopa and haemolytic anaemia. Lancet (1966) 1.21
Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin. Hypertension (1988) 1.17
The plasma half lives and the pharmacological effect of the enantiomers of warfarin in rats. Life Sci II (1972) 1.16
Combined action of methyldopa and bethanidine. Evidence for a synergistic effect. Lancet (1966) 1.11
Effects of methyldopa on prolactin and growth hormone. Br Med J (1976) 1.11
Human brain, cerebrospinal fluid, and plasma concentrations of diphenylhydantoin and phenobarbital. Clin Pharmacol Ther (1974) 1.09
Glucose tolerance in hypertensive patients on long-term diuretic therapy. Lancet (1967) 1.09
Jogger's blockade. Br Med J (Clin Res Ed) (1982) 1.08
Propranolol in the control of blood pressure: a dose-response study. Clin Pharmacol Ther (1980) 1.05
Interactions of benzodiazepines with warfarin. Br Med J (1972) 1.05
Which beta blocker? Br Med J (Clin Res Ed) (1983) 1.00
Clinical implications of enzyme induction. Basic Life Sci (1975) 0.99
Increased glucuronidation of bilirubin in man and rat by administration of antipyrine (phenazone). Clin Sci Mol Med (1974) 0.98
Concern about records of fibrosing colonopathy study. Lancet (2001) 0.96
The effects of long term administration of dopamine on renal function in hypertensive patients. Eur J Clin Pharmacol (1973) 0.95
Advancing the science of medicines regulation: the role of the 21st-century medicines regulator. Clin Pharmacol Ther (2012) 0.94
Clinical pharmacology and therapeutics in undergraduate medical education in the UK: the future. Br J Clin Pharmacol (1994) 0.93
Should every survivor of a heart attack be given a beta blocker? Part II. Evidence from a clinical pharmacological standpoint. Br Med J (Clin Res Ed) (1982) 0.93
Risk sharing and payment by results. Clin Pharmacol Ther (2008) 0.92
Large-dose urography. Is there an optimum dose? Lancet (1967) 0.88
An Indochinese refugee psychiatric clinic: culturally accepted treatment approaches. Am J Psychiatry (1980) 0.88
Vasodilators in heart failure. Br Med J (Clin Res Ed) (1982) 0.87
Expediting patients' access to medicines by improving the predictability of drug development and the regulatory approval process. Clin Pharmacol Ther (2010) 0.87
The challenges of orphan drugs and orphan diseases: real and imagined. Clin Pharmacol Ther (2012) 0.85
Post-marketing strategies for medicines. Clin Pharmacol Ther (2007) 0.85
European perspective on risk management and drug safety. Clin Pharmacol Ther (2011) 0.83
The effects of indomethacin and naproxen on zidovudine pharmacokinetics. Br J Clin Pharmacol (1993) 0.82
What is the nephrogram? Lancet (1967) 0.82
Early access to new medicines. Clin Pharmacol Ther (2008) 0.81
Oral anticoagulant drugs: pharmacokinetic aspects. Semin Hematol (1978) 0.80
Pathophysiological factors influencing drug kinetics. Acta Pharmacol Toxicol (Copenh) (1971) 0.80
Ketanserin--a new antihypertensive agent. J Hypertens Suppl (1986) 0.80
Antipyrine half-life and drug elimination. Clin Pharmacokinet (1980) 0.79
The binding of chlorothiazide to plasma proteins. Biochim Biophys Acta (1971) 0.79
Pharmacoeconomics comes of age? Clin Pharmacol Ther (2008) 0.79
Regulatory review: How do agencies ensure the quality of decision making? Clin Pharmacol Ther (2013) 0.78
Enzyme induction in humans. Clinical aspects--an overview. Pharmacol Ther (1987) 0.78
Labetalol in essential hypertension. Br J Clin Pharmacol (1982) 0.78
Inter-relationship among individual vitamin K-dependent clotting factors at different levels of anticoagulation. Br J Clin Pharmacol (1987) 0.78
Intravenous urography and renal function. Clin Radiol (1968) 0.77
Long term liver blood flow measurements in rats under physiological conditions. Pflugers Arch (1971) 0.77
The third drug in hypertension. Br Med J (Clin Res Ed) (1984) 0.77
Enantiomers of warfarin and phenobarbital. N Engl J Med (1976) 0.76
Effects of dilevalol (R,R-labetalol) compared with nifedipine on heart rate, blood pressure and muscle blood flow at rest and on exercise in hypertensive patients. Br J Clin Pharmacol (1993) 0.75
Warfarin and Distalgesic interaction. Br Med J (1976) 0.75
Adverse effects of captopril in hospital outpatients with hypertension. Postgrad Med J (1990) 0.75
Antiretroviral drug trials. Science (1997) 0.75
Hypertension and hyperuricaemia. Proc R Soc Med (1966) 0.75
Hepatic clearance of propranolol in dogs. Br J Pharmacol (1973) 0.75
Oral anticoagulants--the totem and the taboo. Br Med J (1976) 0.75
Simultaneous onset of malignant hypertension in identical twins. Br Heart J (1973) 0.75
Interactions with warfarin. Br J Clin Pharmacol (1974) 0.75
Factors in the choice of antihypertensive therapy. Br J Clin Pharmacol (1987) 0.75
The Culyer report. Lancet (1995) 0.75
Anticonvulsant pharmacokinetics. Proc R Soc Med (1974) 0.75
Dose-dependent enzyme induction. Br J Pharmacol (1973) 0.75
Prognosis of treated hypertension. Br Heart J (1971) 0.75
Dose - response relationship between warfarin and the metabolism of phylloquinone (vitamin K1) in man. Int J Vitam Nutr Res (1976) 0.75
Clinical pharmacokinetics of drugs against onchocerciasis. Acta Leiden (1990) 0.75
Induction of drug metabolizing enzymes in man. Clin Sci (1970) 0.75
Plasma urea in hypertensive patients. Br Heart J (1976) 0.75
Interaction of arteether with the red blood cell in-vitro and its possible importance in the interpretation of plasma concentrations in-vivo. J Pharm Pharmacol (1992) 0.75
Labetalol in hypertension. Lancet (1977) 0.75
Compliance of hypertensive patients with pharmacological treatment. Hypertension (1983) 0.75
Accentuation of ethanol-induced fatty liver by phenobarbitone. Clin Sci Mol Med (1977) 0.75
The chemotherapy of onchocerciasis. XIV. Studies with mebendazole citrate. Trop Med Parasitol (1990) 0.75
Pharmacokinetic and "potency" of contraceptive steroids. Lancet (1984) 0.75
Drug interactions during metabolism in the liver. Naunyn Schmiedebergs Arch Pharmacol (1977) 0.75
Double-blind comparison of captopril with nifedipine in hypertension complicated by intermittent claudication. Angiology (1992) 0.75
Clinical pharmacology in the 1990s: a personal perspective. Clin Investig (1993) 0.75
Proceedings: A trial of the combination of guanethidine and oxprenolol in hypertension. Scott Med J (1974) 0.75
Value of fluid deprivation in large-dose urography. Lancet (1968) 0.75
Screening methods for measuring liver microsomal enzyme induction by drugs. J Physiol (1969) 0.75
Angiotensin infusion test in hypertension. Am Heart J (1966) 0.75